Compare GPMT & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | PMVP |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 66.1M |
| IPO Year | 2017 | 2020 |
| Metric | GPMT | PMVP |
|---|---|---|
| Price | $1.09 | $1.23 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 258.5K | ★ 290.1K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 12.99% | N/A |
| EPS Growth | ★ 73.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $458.85 | N/A |
| Revenue Next Year | $8.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $1.02 |
| 52 Week High | $3.12 | $1.88 |
| Indicator | GPMT | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 31.82 | 49.82 |
| Support Level | N/A | $1.04 |
| Resistance Level | $1.56 | $1.26 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 18.75 | 26.67 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the commercial property.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.